Why the study?
Does ximelagatran reduce platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation?
Population
24 subjects total: 12 patients with permanent nonvalvular atrial fibrillation and 12 healthy controls.
Comparison
Ximelagatran 36 mg oral twice daily for 5 days. vs Healthy controls receiving the same…
Design
Cohort, open
Follow-up
5 days
Authors
Loading...
Ximelagatran was associated with reduced platelet activation in AF; hypothesis-generating and should not yet change practice.
Does ximelagatran reduce platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation?
Ximelagatran effectively reduces platelet activation and thrombin generation in patients with nonvalvular atrial fibrillation, demonstrating its pharmacodynamic efficacy as a direct thrombin inhibitor.
Wolzt et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: